Allergy Steroid Shot Side Effects: Why This Is Not Immunotherapy

Kenalog (triamcinolone acetonide) is a long-acting depot corticosteroid injection given intramuscularly, typically 40mg, for seasonal allergy symptom relief. It suppresses inflammation broadly — not specifically against allergens — providing 4-6 weeks of relief. It is not approved for this indication by the FDA and is explicitly listed as not recommended for allergic rhinitis by the 2020 AAAAI/ACAAI Rhinitis Practice Parameter (Dykewicz et al., JACI). The UK's NHS discontinued Kenalog for hay fever in 2018 citing an unfavorable risk-benefit profile. A single injection causes HPA-axis suppression lasting 30-40 days, hyperglycemia in diabetic patients, and local tissue atrophy. Repeated injections carry cumulative bone density loss and cataract risk.

Steroid allergy shots (Kenalog/triamcinolone) and allergy immunotherapy shots (SCIT) are completely different medications with different mechanisms, goals, and side-effect profiles. Steroid shots are intramuscular injections of a corticosteroid that broadly suppresses your immune system for 4-6 weeks — no allergen specificity, no disease modification, effects stop when drug wears off. Allergy immunotherapy shots are tiny subcutaneous doses of the actual allergens you're sensitive to, designed to gradually retrain your immune system to tolerate those specific triggers. SCIT is disease-modifying — it changes the underlying allergic disease — with benefits persisting 7-12 years after stopping a completed course. The injection routes differ too: SCIT goes just under the skin on the upper arm; Kenalog goes into the muscle.

Yes — corticosteroid injections cause predictable blood glucose elevation, particularly in patients with diabetes or prediabetes. Habib and Safia (Clin Rheumatol 2009) documented that blood glucose can rise significantly for 2-5 days following a depot corticosteroid injection, sometimes reaching 300+ mg/dL in diabetic patients. The glucocorticoid receptor activation in liver and muscle cells stimulates glucose production and reduces insulin sensitivity. Patients with diabetes should monitor blood glucose closely for at least 5 days after receiving a corticosteroid injection and have a management plan in place — typically insulin adjustment for insulin-dependent diabetics. Non-diabetic patients may also experience transient glucose elevation but are less likely to require intervention.

Yes — a single depot corticosteroid injection meaningfully suppresses your immune system for the duration of drug action (approximately 30-40 days for Kenalog 40mg). Glucocorticoids reduce neutrophil, lymphocyte, eosinophil, and macrophage activity — which is why they suppress allergic symptoms but also why they increase susceptibility to certain infections during the suppression window. This is one of the reasons professional allergy organizations explicitly recommend against repeated depot steroid injections for allergic rhinitis management. Allergy immunotherapy shots (SCIT), by contrast, do not suppress the immune system — they redirect it via regulatory T-cell induction and IgG4 blocking antibody production, without any period of generalized immune suppression.

Depot corticosteroid injections for allergies are often administered by primary care physicians, urgent care providers, or family practitioners who may not specialize in allergy and immunology. The AAAAI and ACAAI recommendation against their use for allergic rhinitis is a guideline developed by allergy specialists — it may not be universally known or followed in generalist practice settings. Patients may also specifically request them because of the convenience of a single treatment providing weeks of relief. It's worth knowing that board-certified allergists — the specialists with the deepest training in allergy mechanisms and treatment — consistently advise against these injections and offer disease-modifying alternatives instead. If you've been receiving seasonal allergy steroid shots, a consultation with an allergist is a reasonable next step.

Annual corticosteroid injections for allergies carry cumulative steroid burden risks over time. Van Staa et al. (JBMR 2000) documented dose-dependent osteoporosis risk with cumulative systemic corticosteroid exposure — each Kenalog injection is equivalent to approximately 30 days of oral prednisone. Over years of annual injections, bone density can decline significantly. Posterior subcapsular cataracts are documented with repeated systemic steroid exposure (Urban and Cotlier, JAMA 1986). Cumulative HPA-axis suppression, diabetes risk escalation, weight gain, and increased infection susceptibility are additional concerns. The risk-benefit calculation that makes a single emergency steroid injection acceptable shifts unfavorably when the pattern becomes annual or more frequent. Disease-modifying alternatives — immunotherapy — address the underlying allergic disease rather than repeatedly suppressing its symptoms.